Drugs / DCB-BO1301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02994498 | Mar 2023 → Sep 2025 | melanoma | Chung Mei Biopharma Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCB-BO1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02994498 ↗ |
| Route | Oral | “1, 2, or 3 capsules, three times a day, oral” NCT02994498 ↗ |